-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Candel Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2020 to Q2 2025.
- Candel Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2025 was -$11.2M, a 30.4% decline year-over-year.
- Candel Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2025 was -$36.2M, a 1.55% decline year-over-year.
- Candel Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$33.4M, a 13.1% increase from 2023.
- Candel Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$38.4M, a 10.6% decline from 2022.
- Candel Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$34.7M, a 35% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)